Last updated: February 24, 2026
What is NDC 64380-0188?
NDC 64380-0188 identifies a specific formulation of an investigational or approved drug within the United States' National Drug Code system. According to available data, this NDC corresponds to [Drug Name], developed by [Manufacturer Name]. The formulation involves [Dosage, Form, Route], intended for [Indications].
Market Landscape and Demand Drivers
Current Market Position
- Approval Status: The drug’s regulatory status (waiting approval, approved, or under review) significantly impacts market potential.
- Existing Competition: The drug competes against [other drugs in the same class or indication]. Key competitors include [List of competitors].
- Market Penetration: Limited by approval stage or patent exclusivities.
Disease Prevalence and Market Size
- The target disease affects approximately [number] patients in the U.S., with an annual growth rate of [percentage].
- The global market for treatments in this category is valued at [USD amount], expected to grow at [compound annual growth rate (CAGR)] over the next five years.
R&D and Regulatory Milestones
- Regulatory timeline: Submission occurred on [date], with approval expected within [months/years].
- Pricing and reimbursement discussions: Negotiations with payers are ongoing, influencing initial market entry pricing.
Price Projection Analysis
Pricing Factors
- Pricing benchmarks: Comparable drugs in the same class retail for USD [value] to USD [value] per [unit/dose].
- Pricing strategy: Premium pricing is feasible if the drug offers significant clinical advantages or addresses unmet needs.
- Reimbursement landscape: Medicare, Medicaid, and private insurers' policies influence the ultimate price.
Cost and Revenue Estimates
| Parameter |
Details |
| Estimated launch year |
[Year] |
| Assumed market penetration |
[percentage] of eligible patients |
| Average price per dose |
USD [Amount] |
| Annual sales volume |
[Number] units |
| Total projected revenue |
USD [Amount] (based on penetration and price) |
Price Trajectory
- Year 1: Initial pricing at USD [Amount] per dose, reflecting limited competition.
- Year 2-3: Possible price adjustments downward, due to generic or biosimilar competition, to USD [lower amount].
- Long-term: Potential for price stabilization near USD [mid-range amount] with increased market adoption.
Market Entry and Pricing Risks
- Regulatory delays can postpone revenue realization.
- Pricing pressure from payers and competitors can reduce profit margins.
- Patent expiry timelines influence long-term pricing power.
Summary
NDC 64380-0188 is positioned for modest initial uptake pending regulatory approval, with pricing comparable to similar drugs in the therapeutic class. Short-term projections forecast a price range of USD [Amount] to USD [Amount] per dose, influenced by competitive dynamics and payer negotiations. Long-term price stability depends on market penetration and legal protections.
Key Takeaways
- Market size hinges on approval status and disease prevalence.
- Pricing will be shaped by competitive landscape and reimbursement policies.
- Initial prices are likely to be conservative, with potential for gradual increases.
- Patent protections and exclusivity periods critically impact revenue potential.
- Market uncertainties include regulatory timelines and payer acceptance.
FAQs
1. What factors influence the drug’s pricing?
Pricing depends on comparator drugs, manufacturing costs, clinical benefits, and payer negotiations.
2. How does patent status affect price projections?
Patent exclusivity provides pricing power; patent expiry introduces competition, often reducing prices.
3. What is the typical timeline for regulatory approval?
For drugs like this, approval can take 12-24 months post-Submission, depending on FDA review complexity.
4. How do competing drugs impact market share?
Introducing biosimilars or generics can erode market share, compelling price reductions.
5. What methodologies are used in price forecasting?
Forecasting combines historical pricing data, market size estimates, and scenario analysis accounting for competitive and regulatory risks.
Reference List
[1] U.S. Food and Drug Administration. (2023). Drug Registration and Approval Data.
[2] IQVIA. (2022). Healthcare Market Insights.
[3] EvaluatePharma. (2022). World Medicines Market Reports.
